TrialInternational journal of cancer2021

A higher ctDNA fraction decreases survival in regorafenib-treated metastatic colorectal cancer patients. Results from the regorafenib's liquid biopsy translational biomarker phase II pilot study.

Matthias Unseld et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.